摘要
目的探讨胸腺肽联合抗结核药治疗复治涂阳肺结核的临床效果。方法选取本院2010年2月～2013年2月收治的90例复治涂阳肺结核患者，随机分为对照组和观察组，对照组患者给予常规化疗方案治疗，观察组患者在化疗基础上给予胸腺肽联合抗结核药治疗，比较两组的临床治疗效果、痰菌阴转率、肺部病变情况、肺内空洞闭合情况以及不良反应发生情况。结果观察组总有效率为95．6％，痰菌阴转率为77．8％，空洞闭合率为77．8％；对照组总有效率为77．8％，痰菌阴转率为60．0％，空洞闭合率为53．3％；两组差异有统计学意义（P〈O．05）。两组患者不良反应发生率差异无统计学意义（P〉O．05）。结论胸腺肽联合抗结核药治疗复治涂阳肺结核的临床效果显著。
Objective To observe the clinical efficacy of thymosin combined with anti-tubercular drug in the treatment of retreatment smear-positive pulmonary tuberculosis.Methods 90 cases of patients with retreatment smear-positive pulmonary tuberculosis treated in our hospital from February 2010 to February 2013 were selected and divided into the control group and the observation group randomly.The control group was treated with conventional chemotherapy regi- mens,and the observation group was treated with anti-tubercular drug based on the control group.The clinical results, sputum negative rate,lung disease,the lung cavity closure as well as the occurrence of adverse reactions was compared between two groups.Results The total effective rate of observation group was 95.6%,sputum negative rate was 77.8%, cavity closure rate was 77.8%.The total effective rate of control group was 77.8%,sputum negative rate was 60.0%,cavi- ty closure rate was 53.3%.The difference was significant of two groups （P〈0.05）.Two groups of patients on the incidence of adverse drug reactions had no significant difference （P〉0.05）.Conclusion Thymosin combined with anti-tubercular drug in treating retreatment smear-positive pulmonary tuberculosis has evident clinical efficacy.
出处
《中国当代医药》
2014年第2期72-74,共3页
China Modern Medicine
关键词
复治涂阳肺结核
胸腺肽
抗结核药
临床疗效
Retreatment smear-positive pulmonary tuberculosis
Thymosin
Anti-tubercular drug
Clinical efficacy
